Northeast Georgia Medical Center

Summary

Northeast Georgia Medical Center is a medical facility located in Gainesville, Georgia. This center is recognized for care of Lung Cancer, Breast Cancer, Ovarian Cancer, Non-Small Cell Lung Cancer, Fallopian Tube Cancer and other specialties. Northeast Georgia Medical Center is involved with conducting 254 clinical trials across 317 conditions. There are 8 research doctors associated with this hospital, such as Charles H. Nash, Habib Samady, MD, Pranav Kansara, MD, and Ugochukwu Egolum, MD.

Top PIs

Clinical Trials running at Northeast Georgia Medical Center

Lung Cancer

Colorectal Cancer

Pancreatic Cancer

Non-Small Cell Lung Cancer

Ovarian Cancer

Bladder Cancer

Breast cancer

Prostate Cancer

Breast Cancer

Lymphoma

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.

Recruiting

2 awards

Phase 3

27 criteria

Amivantamab

for Non-Small Cell Lung Cancer

This phase II Expanded Lung-MAP treatment trial tests how well amivantamab-subcutaneous (SC) works in treating patients patients with MET amplification non-small cell lung cancer. Amivantamab-SC is a drug that reduces extra copies of the MET gene, a change present in your tumor. Giving amivantamab-SC may lower the chance of the growth or spread of advanced non-small cell lung cancer that has extra copies of the MET gene in the tumor.

Recruiting

1 award

Phase 2

16 criteria

Cancer Cachexia

for Colorectal, Lung, and Pancreatic Cancer

This study evaluates cancer-related weight and muscle mass loss, symptoms, and physical function (cachexia) in patients undergoing treatment for colorectal, lung, or pancreatic cancer that cannot be removed by surgery (unresectable) or is stage IV. Patients with these cancer types are at risk for developing cancer cachexia (CC), which is defined as weight loss, muscle loss, and fat loss due to cancer. CC has been associated with reduced physical performance, impaired quality of life, and poorer survival. Many studies that have evaluated treatments for cancer-related weight and muscle loss have aimed to treat all patients with weight loss exactly the same and, unfortunately, have not been successful. Like different cancer types, weight and muscle loss related to cancer may have different causes in different individuals and the best treatment strategy for this condition may not be a one-size-fits-all approach. Information gathered from this study may help researchers develop new diagnostic criteria for CC and design better treatments and clinical trials for cancer-related weight and muscle loss in the future to improve the quality of life in patients with advanced colorectal, lung, or pancreatic cancer.

Recruiting

1 award

N/A

7 criteria